GlassScriptPhysician profile
Sara Jane Mcgee
NPI 1437144409
$2,278.84
in general payments reported to CMS, 2019-2025
22 companies · $176 in 2025
The $176 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $273 · 2020: $421 · 2021: $372 · 2022: $732 · 2023: $220 · 2024: $84.98 · 2025: $176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $481.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $481.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $218.50 | 2019-2025 | Verzenio, Jaypirca |
| Amgen INC. | $216.43 | 2020-2021 | |
| Incyte Corporation | $193.94 | 2022-2023 | Jakafi |
| Janssen Biotech, INC. | $170.18 | 2019-2025 | Tecvayli, Darzalex |
| Merck Sharp & Dohme LLC | $163.55 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $151.63 | 2020-2025 | Calquence |
| E.R. Squibb & Sons, L.L.C. | $137.17 | 2019-2021 | |
| Abbvie INC. | $133.49 | 2021-2022 | |
| Astellas Pharma US INC | $131.02 | 2022-2025 | Cresemba |
| Seagen INC. | $125.00 | 2022 | |
| Alexion Pharmaceuticals, INC. | $120.94 | 2022 | |
| Pfizer INC. | $89.64 | 2019-2021 | |
| Celgene Corporation | $87.27 | 2019-2024 | Reblozyl |
| Genzyme Corporation | $85.13 | 2024-2025 | |
| Genentech USA, INC. | $48.03 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $46.45 | 2021 | |
| Taiho Oncology, INC. | $33.93 | 2019-2024 | |
| Daiichi Sankyo INC. | $32.16 | 2020-2025 | Datroway |
| Array Biopharma INC | $30.29 | 2020-2021 | |
| Baxter Healthcare | $29.86 | 2020 | |
| Puma Biotechnology, INC. | $21.02 | 2024 | |
| Glaxosmithkline, LLC. | $13.21 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Mcgee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.